Apelin-36(human) TFA

Apelin-36(human) TFA, an endogenous agonist of the orphan G protein-coupled receptor APJ, exhibits a potent EC50 of 20 nM and high affinity (pIC5 50 = 8.61) for human APJ receptors in HEK 293 cells. It is involved in significant cardiovascular and metabolic activities. Furthermore, Apelin-36(human) TFA can inhibit the entry of certain HIV-1 and HIV-2 strains into NP2/CD4 cells expressing the APJ receptor. [1] [2] [3] [4]

Kisspeptin-10, human TFA is a potent vasoconstrictor and angiogenesis inhibitor. Kisspeptin-10, human TFA acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression

Apelin-17 (human, bovine) acetate is an endogenous apelin receptor agonist. Potently inhibits forskolin-stimulated cAMP accumulation (pIC50 = 9.94).

Gastrin-Releasing Peptide, human(TFA) is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate the G cells of the stomach release GRP, which stimulates the G cells to release gastrin.

Peptide YY (PYY) (3-36), human (Peptide YY (3-36)) is a gut hormone peptide. Peptide YY (PYY) (3-36), human acts as a Y2 receptor agonist to reduce appetite.

Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ～1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a 16-1 expression.

MCH (human, mouse, rat) TFA is a potent peptide agonist for MCH receptors, demonstrating strong affinity with binding IC 50 values of 0.3 nM for MCH1R and 1.5 nM for MCH2R. It is notably effective against MCH-2R in a CHO cell line, as evidenced by the mobilization of intracellular calcium measured with FLIPR, revealing functional activation EC 50 values of 3.9 nM for MCH-1R and 0.1 nM for MCH-2R [1].

TIP39, a neuropeptide and an agonist for the parathyroid hormone receptor type 2 (PTH2R), effectively increases cAMP levels in COS-7 cells featuring recombinant PTH2R from humans or rats (EC50s = 0.5 and 0.8 nM, respectively), as well as in F-11 cells that naturally express PTH2R (EC50 = 1.15 nM). Furthermore, TIP39 at 1 nM halts the cell cycle at the G0/G1 phase and reduces Sox9 expression, a crucial regulator of cartilage differentiation, in CFK2 rat chondrocytes. Additionally, administering 100 pmol/animal of TIP39 reduces the immobility period in the forced swim test in mice, indicating a potential antidepressant effect.

Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2.

PAMP-12(human, porcine) TFA, a significant constituent of immunoreactive (ir)-PAMP, derives from the adrenomedullin precursor and functions as a potent hypotensive peptide involved in cardiovascular regulation [1].

Obestatin(human) TFA, an endogenous peptide originating from the same prepropeptide as ghrelin, is known to suppress food intake and reduce weight gain in rats.

TNF-α (31-45), human (TFA) is a peptide of tumor necrosis factor-α.

Klotho-derived peptide 1 (KP1) (56-87), a peptide originating from the human Klotho protein, disrupts TGF-β signaling by binding to TGF-β receptor types 1 and 2 (TGFBR1 and TGFBR2; Kds = 1.41 and 14.6 µM, respectively). Preincubation with KP1 at a concentration of 10 µg/ml hinders the TGF-β-induced escalation of fibronectin and α-smooth muscle actin (α-SMA) levels in NRK-49F rat fibroblasts. Furthermore, in vivo studies reveal that KP1, administered at 1 mg/kg per day, preferentially accumulates in damaged kidneys, leading to significant reductions in serum creatinine and blood urea nitrogen levels, indicators of improved kidney function. Additionally, it decreases kidney fibrosis in mouse models of unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury-induced renal fibrosis.

PACAP-38 (31-38), human, mouse, rat (TFA) demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal.

Endogenous APJ receptor agonist (EC50 = 20 nM) that is secreted by adipocytes. Binds with high affinity to human APJ receptors expressed in HEK 293 cells (pIC50= 8.61). Involved in regulation of cardiovascular function, fluid homeostasis and feeding. Bloc

Human LL-37 is a 37 amino acid cationic (6+) peptide and has been widely studied. LL-37 penetrates the bacterial membrane and forms pores in the membrane.

Fibrinopeptide A, human is a 16-residue short polypeptide cleaved from fibrinogen by thrombin. Fibrinopeptide A, human locates at the NH2-termini of the Aα chain.The conversion of monomeric fibrinogen into polymeric fibrin is mediated by thrombin, which b

Tau protein (592-597), Human (TFA) is a peptide fragment of human Tau protein.

Endogenous agonist at orexin receptors (Ki values are 20 and 38 nM for OX1 and OX2 receptors respectively). Stimulates feeding following central administration and may be involved in the control of sleep-wake cycle and other hypothalamic functions.

Neuropeptide W-23 (human) (NPW-23) TFA, representing the active form of Neuropeptide W, functions as an endogenous agonist for both NPBW1 (GPR7) and NPBW2 (GPR8) receptors [1].

Apelin-13 is an endogenous ligand of APJ receptor, and the EC 50 value of activated G protein coupled receptor is 0.37 nM.

Nocistatin (human) TFA inhibits the allodynia and hyperalgesia induced by nociceptin and mitigates pain triggered by prostaglandin E2 [1].

Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFAis a kind of NH2 TFA truncated at the end of the quality of adrenal medullary analogue, is a kind of quality of adrenal medullary receptor antagonist.

Neuropeptide Y (3-36) (human, rat) is a metabolite of neuropeptide Y (NPY) generated by dipeptidyl peptidase-4 (DPP4). Known as a selective Y2 receptor agonist, Neuropeptide Y (3-36) (human, rat) effectively reduces the release of norepinephrine via the Y2 receptor[1][2].

GLP-1 (1-36) amide (human, rat) TFA, a molecular variant of GLP-1 (7-36) amide, can induce [14C]aminopyrine accumulation in enzymatically dispersed enriched rat parietal cells [1].

Urotensin II (114-124), human TFA, is an 11-amino acid residue peptide with a strong vasoconstrictor effect. This compound acts as an agonist for the orphan receptor GPR14.

GIP (1-30) amide (Human) TFA is a glucose-dependent insulinotropic polypeptide fragment. Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions.

PACAP (6-38), human, ovine, rat TFA is a potent PACAP receptor antagonist with IC50s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2, respectively.

Amylin, amide, human TFA, a 37-amino acid polypeptide, functions as a pancreatic hormone that is cosecreted with insulin, playing distinct roles in metabolism and glucose homeostasis. It regulates blood sugar by inhibiting glucagon secretion, delaying gastric emptying, and promoting satiety [1].

Endogenous APJ receptor agonist that is secreted by adipocytes. Binds with high affinity to APJ receptors (IC50 = 5.4 nM) and potently inhibits cAMP production in vitro (EC50 = 0.52 nM). Involved in regulation of cardiovascular function, fluid homeostasis

(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1].

Biotin-β-Amyloid (1-42), human TFA, also known as Biotin-Amyloid β-Peptide (1-42) (human) TFA, is a biotin-labeled 42-amino acid peptide implicated in the pathogenesis of Alzheimer's disease [1].

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

LL-37 (18-37), an antimicrobial peptide fragment of LL-37, exhibits activity against S. aureus and C. albicans, with minimum lethal concentrations of 4 µM and 10 µM, respectively. Additionally, it inhibits E. histolytica trophozoites growth at concentrations between 10 to 50 µM.

Interphotoreceptor retinoid-binding protein (1-20) (IRBP1-20), a dodecapeptide fragment of retinoid-binding protein 3, plays a crucial role in pigment regeneration by facilitating the transport of retinol and retinal between photoreceptor cells and the retinal pigment epithelium. It has been utilized to provoke autoimmune uveoretinitis in C57BL/6 mice, possessing the H-2b haplotype. Furthermore, IRBP1-20 at a concentration of 3 µM enhances the secretion of IL-4, IL-5, and IL-6 from primary mouse spleen lymphocytes. Immunization and subsequent rechallenge with IRBP1-20 lead to increased ear swelling, inflammation of ocular blood vessels, infiltration by immune cells, damage to the photoreceptor layer, and retinal detachment in IFN-γ-deficient mice.

TNF-α (31-45), human (TFA) is a peptide of tumor necrosis factor-α. Tumour necrosis factor alpha (TNF alpha) is an inflammatory cytokine that induces necrosis or apoptosis [1] .

β-Melanocyte Stimulating Hormone (MSH), human TFA, is a 22-residue peptide that functions as an endogenous agonist for the melanocortin-4 receptor (MC4-R) [1].

Human β-CGRP TFA (β-CGRP, human TFA) is a calcitonin peptide that functions through interaction with the calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP) complex, demonstrating IC50 values of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2, respectively, in cellular assays [1].

GLP-1(32-36)amide TFA, originating from the C-terminal end of the glucoregulatory hormone GLP-1, is a pentapeptide that has demonstrated the ability to mitigate weight gain and regulate glucose metabolism throughout the body in diabetic mice [1] [2].

Human Growth Hormone-Releasing Factor TFA, also known as Growth Hormone-Releasing Factor Human TFA, is a hypothalamic polypeptide that promotes the production and release of growth hormone (GH) through its interaction with the Growth Hormone-Releasing Hormone Receptor (GHRHR) on anterior pituitary cells [1].

CART(62-76)(human,rat) TFA, a neuropeptide encompassing residues 62-76 of the CART peptide, exhibits neurotransmitter-like properties. It is capable of modulating the activity of the striatal noradrenergic system, as well as the corticostriatal and hypothalamic serotoninergic (5-HT) systems in the rat brain [1].

[Ala11,D-Leu15]-Orexin B(human) TFA is a potent, selective agonist for the orexin-2 receptor (OX2), demonstrating 400-fold higher selectivity for OX2 (EC 50 =0.13 nM) compared to the orexin-1 receptor (OX1) with an EC 50 of 52 nM.

Lys-γ3-MSH(human) TFA, a melanocortin peptide originating from the C-terminal fragment of pro-opiomelanocortin (POMC), enhances the steroidogenic response of rat adrenal glands to adrenocorticotrophin (ACTH). It is a potent stimulator of lipolysis, demonstrating an apparent EC50 of 3.56 nM, by activating hormone-sensitive lipase (HSL) and Perilipin A, leading to lipolysis [1] [2].

Neuropeptide Y (13-36), amide, human is a neuropeptide Y receptor agonist.

Neuropeptide Y (NPY) (3-36) is a C-terminal fragment of NPY, a neuropeptide involved in controlling appetite, blood pressure, cardiac contractility, and intestinal secretion. NPY (3-36) is an endogenous peptide produced by cleavage of NPY by dipeptidyl peptidase 4 (DPP-4). It binds selectively to the NPY receptor Y2 (Ki = 0.41 nM in CHP 234 cells) over the Y1 receptor, where it does not bind at concentrations up to 1 μM. NPY (3-36) (0.1 nM) increases migration of human umbilical vein endothelial cells (HUVECs) by 80% after 12 hours in an in vitro wound closure assay. NPY (3-36) corresponds to residues 3-36 of the human and rat protein sequence.

MART-1 (26-35) (human) TFA is an amino acid residue of 26-35 protein.

Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor, it is a kind of pancreatic hormone synthesized by post-translational processing of proglucagon.

Adrenocorticotropic Hormone (ACTH) (18-39), human TFA (CLIP human TFA) is a corticotropinlike intermediate lobe peptide, it is is produced in the melanotrophs of the intermediate lobe of the pituitary.

FibrinopeptideB,human is a 14-amino acid polypeptide released from the amino terminus of the fibrinogen segment.

Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3].